Related Experiment Video
Updated: Apr 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor
Kaitlin Anstett1, Thibault Mesplede2, Maureen Oliveira2
1McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada.
Abstract:
The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections with DTG, using viruses resistant to older INSTIs and infectivity and resistance assays, and showed that the presence of the E92Q or N155H substitution was compatible with the emergence of R263K, whereas the G140S Q148R, E92Q N155H, G140S, Y143R, and Q148R substitutions were not.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
12:53Bidirectional Retroviral Integration Site PCR Methodology and Quantitative Data Analysis Workflow
Published on: June 14, 2017
Related Concept Videos
Viral Mutations
Retroviruses
Non-LTR Retrotransposons
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Point and Frameshift Mutations